Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus

Background. Dipeptidyl peptidase­4 inhibitors, ­having incretin activity, influence the main pathogenetic mecha­nisms of type 2 diabetes mellitus (DM). Vildagliptin is an innovative dipeptidyl peptidase­4 inhibitor with unique pharmacokinetic characteristics, the efficacy and safety of which have be...

Full description

Bibliographic Details
Main Author: V.I. Pankiv
Format: Article
Language:English
Published: Publishing House Zaslavsky 2019-10-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
type 2 diabetes mellitus
vildagliptin
glycated hemoglobin
insulin resistance
Online Access:http://iej.zaslavsky.com.ua/article/view/186055

Internet

http://iej.zaslavsky.com.ua/article/view/186055

Similar Items